Knowledge Hub · I-131 Therapy
The clinical + regulatory framework around radioactive-iodine therapy.
I-131 therapy sits inside a two-layer framework: the clinical guidelines (ATA, EANM, SNMMI) defining who, when and how much; and the regulatory chain (AERB SC/MED-4, IAEA SRS 63, ICRP Publication 94) defining ward design, waste handling and patient-release criteria. Six anchor documents cover both.
Standards framework
Six documents that shape the therapy programme.
EANM procedure guidelines for therapy with iodine-131 (I-131) (2022)
The European Association of Nuclear Medicine's updated procedure guideline for I-131 therapy — indications for differentiated thyroid cancer ablation, hyperthyroidism, benign nodular disease, activity selection, patient preparation, dosimetry-based vs empiric activity choice.
Open standard →
American Thyroid Association Management Guidelines for Adult Patients with Thyroid Nodules and Differentiated Thyroid Cancer
The ATA management guideline — the definitive reference on when radioactive-iodine therapy is indicated in DTC, activity-selection tiers by risk stratification, and post-ablation whole-body-scan workflow.
Open standard →
SNMMI/EANM Practice Guideline for Post-Therapy Imaging in DTC Patients
Post-therapy planar + SPECT/CT scan workflow after I-131 ablation. Anchors the "why we image day-3 to day-10 post-ablation" answer and defines the imaging QC that closes out an ablation cycle.
Open standard →
Safety Code for Nuclear Medicine Facilities
India's regulatory code for nuclear medicine — includes the therapy-ward design requirements, isolation-room air-change rate, waste-handling for I-131 patient excreta, and the discharge-activity thresholds patients must fall below before release.
Open standard →
Release of Patients After Radionuclide Therapy
The IAEA guide on the calculations, hospital-stay logic, radiation-protection advice to household + travel companions, and hospital-discharge dose-rate thresholds for I-131 therapy patients.
Open standard →
Release of Patients After Therapy with Unsealed Radionuclides
The ICRP framework document behind IAEA SRS 63 — dose constraints for family members and the public, the dose-rate calculation logic feeding the AERB / IAEA release criteria.
Open standard →
Peer-reviewed literature
Three references the therapy team builds SOPs on.
EANM procedure guidelines for therapy with iodine-131
Silberstein EB, Alavi A, Balon HR, et al.
The definitive procedure guideline. Reviewed inside every teaching-hospital curriculum for I-131 therapy in Europe and India.
Read source →
American Thyroid Association Management Guidelines for Adult Patients with Thyroid Nodules and Differentiated Thyroid Cancer
Haugen BR, Alexander EK, Bible KC, et al.
The ATA management guideline — the reference for activity-selection tiers by DTC risk stratification.
Read source →
Practical management of radioactive iodine therapy for differentiated thyroid cancer
Van Nostrand D
Practical workflow-oriented review, cited widely in Indian teaching-hospital I-131 curricula.
Read source →
Literature Radar · auto-updated daily
Latest I-131 therapy research
Peer-reviewed papers on I-131 thyroid therapy, auto-updated from Europe PMC + OpenAlex.
- Peer-ReviewedPubMedEuropean journal of endocrinology · 2026
Second Primary Malignancy Risk Following Radioactive Iodine Therapy for Thyroid Cancer: A Population-based Matched Cohort Study in Taiwan.
Lin SF, Lu YL, Wu CL et al.
- Peer-ReviewedPubMedEuropean radiology · 2026
DSDFF-YOLO: an automated computer-aided diagnostic method for post-therapy radioiodine whole-body scan.
Chen L, Yu F, Zhao J et al.
- Peer-ReviewedPubMedEndocrine · 2026
The impact of RET fusions on radioiodine avidity and prognosis in patients with distant metastatic papillary thyroid cancer.
Shi K, Zhang X, Huang S et al.
- Peer-ReviewedPubMedApplied radiation and isotopes · 2026
A hybrid biokinetic-Monte Carlo framework for internal dosimetry of I-131 using a modified MIRD phantom.
Ezzati AO, Arasi M.
- Peer-ReviewedPubMedJournal of nuclear medicine · 2026
Recombinant Human Thyrotropin Versus Thyroid Hormone Withdrawal for Radioactive Iodine Therapy in Metastatic Differentiated Thyroid Cancer: A Multicenter Retrospective Study.
Hong CM, Gil J, Cheon GJ et al.